Media.Player

pH-"Tunable" Nano-Particle Drug Delivery System

Technology Application

These features should prove extremely relevant for clinical applications, from cancer to ophthalmology, where increased efficacy and reduce drug toxicity can enhance the therapeutic profile and/or extend patient life for promising and useful drugs.

Detailed Technology Description

A new class of linkers has been developed to address these limitations. These linkers: Undergo controlled hydrolysis at physiological temperature and in mild aqueous, acidic environments.Can be tuned to hydrolyze with half-lives from thirty minutes to greater than nine months. Accommodate a wide range of biocompatible drug carriers. Flexibly conjugate to a wide variety of drugs (via alcohol, amine, or imidazole).

Supplementary Information

Patent Number: US8575359B2
Application Number: US2008295858A
Inventor: Yang, Jerry | Kong, Seong Deok | Luong, Alice | Howell, Stephen
Priority Date: 4 Apr 2006
Priority Number: US8575359B2
Application Date: 20 Sep 2010
Publication Date: 5 Nov 2013
IPC Current: C07D023300 | C07D023302 | C07D023354 | C07D023360 | C07H001524
US Class: 5483001 | 5360064 | 5483415
Assignee Applicant: The Regents of the University of California
Title: Acid-sensitive linkers for drug delivery
Usefulness: Acid-sensitive linkers for drug delivery
Summary: As acid-sensitive linkers for delivering drugs useful for treating cancer and for inhibiting cell proliferation and growth of cancer cells.
Novelty: New imidazole derivatives, as acid-sensitive linkers for delivering drugs useful for treating cancer and for inhibiting cell proliferation and growth of cancer cells

Industry

Disease Diagnostic/Treatment

Sub Category

Cancer/Tumor

Application No.

8575359

Others

Intellectual Property Info

See issued patent, below.

Related Materials

Yang Research

Additional Technologies by these Inventors

• Ultrasensitive, Ion Channel-Based Sensors
• Lead Compounds for Diagnosis and Therapy of Alzheimer's Disease
• Fluorescent Amyloid Binding Agents for Diagnosis of Alzheimer's Disease

Tech ID/UC Case

19435/2006-140-0

Related Cases

2006-140-0

*Abstract

Target-selective drug delivery remains a challenge for various therapeutic applications and particularly for cancer. Current targeting strategies include formulation and encapsulation for preferential release in the acidic tumor environment as well as covalent conjugation via linkers sensitive to pH, to oxygen levels, or to disease-specific enzymes. These approaches have been limited by:

• Stringent requirements on linkable drugs and carriers.
• Inflexible rates of release.
• Insufficient target/tumor-specificity of relevant enzymes.

*IP Issue Date

Nov 5, 2013

*Principal Investigator

Name: Stephen Howell

Department:

Name: Seong Deok Kong

Department:

Name: Alice Luong

Department:

Name: Jerry Yang

Department:

Country/Region

USA